Avricore Health Inc (AVCR) - Net Assets
Based on the latest financial reports, Avricore Health Inc (AVCR) has net assets worth CA$389.56K CAD (≈ $281.80K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$563.12K ≈ $407.36K USD) and total liabilities (CA$173.56K ≈ $125.55K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Avricore Health Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$389.56K |
| % of Total Assets | 69.18% |
| Annual Growth Rate | 6.54% |
| 5-Year Change | -82.27% |
| 10-Year Change | -79.69% |
| Growth Volatility | 200.15 |
Avricore Health Inc - Net Assets Trend (2000–2025)
This chart illustrates how Avricore Health Inc's net assets have evolved over time, based on quarterly financial data. See Avricore Health Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Avricore Health Inc (2000–2025)
The table below shows the annual net assets of Avricore Health Inc from 2000 to 2025. For live valuation and market cap data, see Avricore Health Inc (AVCR) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CA$389.56K ≈ $281.80K |
-80.20% |
| 2024-12-31 | CA$1.97 Million ≈ $1.42 Million |
-2.05% |
| 2023-12-31 | CA$2.01 Million ≈ $1.45 Million |
+2.29% |
| 2022-12-31 | CA$1.96 Million ≈ $1.42 Million |
-10.60% |
| 2021-12-31 | CA$2.20 Million ≈ $1.59 Million |
+407.67% |
| 2020-12-31 | CA$-714.04K ≈ $-516.53K |
-53.41% |
| 2019-12-31 | CA$-465.45K ≈ $-336.70K |
-152.54% |
| 2018-12-31 | CA$885.97K ≈ $640.89K |
-64.53% |
| 2017-12-31 | CA$2.50 Million ≈ $1.81 Million |
+30.25% |
| 2016-12-31 | CA$1.92 Million ≈ $1.39 Million |
-40.93% |
| 2015-12-31 | CA$3.25 Million ≈ $2.35 Million |
-3.18% |
| 2014-12-31 | CA$3.35 Million ≈ $2.43 Million |
+405.73% |
| 2013-12-31 | CA$663.10K ≈ $479.67K |
+51.85% |
| 2012-12-31 | CA$436.69K ≈ $315.89K |
+133.05% |
| 2011-12-31 | CA$-1.32 Million ≈ $-955.71K |
-23.88% |
| 2010-12-31 | CA$-1.07 Million ≈ $-771.49K |
-545.68% |
| 2009-12-31 | CA$239.30K ≈ $173.10K |
-86.13% |
| 2008-12-31 | CA$1.73 Million ≈ $1.25 Million |
-30.30% |
| 2007-12-31 | CA$2.48 Million ≈ $1.79 Million |
+217.48% |
| 2006-12-31 | CA$779.90K ≈ $564.17K |
+395.59% |
| 2005-12-31 | CA$157.37K ≈ $113.84K |
-41.94% |
| 2004-12-31 | CA$271.03K ≈ $196.06K |
-66.13% |
| 2003-12-31 | CA$800.22K ≈ $578.87K |
+337.32% |
| 2002-12-31 | CA$182.98K ≈ $132.37K |
-0.78% |
| 2001-12-31 | CA$184.42K ≈ $133.41K |
+130.67% |
| 2000-12-31 | CA$79.95K ≈ $57.83K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Avricore Health Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3425073300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$34.65 Million | 8895.29% |
| Total Equity | CA$389.56K | 100.00% |
Avricore Health Inc Competitors by Market Cap
The table below lists competitors of Avricore Health Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
McChip Resources Inc
V:MCS
|
$3.66 Million |
|
Foresight Autonomous Holdings Ltd
TA:FRSX
|
$3.67 Million |
|
Yu Group PLC
LSE:YU
|
$3.67 Million |
|
Fragbite Group AB
ST:FRAG
|
$3.67 Million |
|
Kakel Max AB (publ)
ST:KAKEL
|
$3.66 Million |
|
Capstone Holding Corp. Common Stock
NASDAQ:CAPS
|
$3.66 Million |
|
XP Chemistries AB
ST:XPC
|
$3.66 Million |
|
Hubify Ltd
AU:HFY
|
$3.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Avricore Health Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,967,727 to 389,564, a change of -1,578,163 (-80.2%).
- Net loss of 1,858,747 reduced equity.
- Other factors increased equity by 280,584.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-1.86 Million | -477.14% |
| Other Changes | CA$280.58K | +72.03% |
| Total Change | CA$- | -80.20% |
Book Value vs Market Value Analysis
This analysis compares Avricore Health Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.00x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.02x to 13.00x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | CA$2.72 | CA$0.05 | x |
| 2001-12-31 | CA$3.24 | CA$0.05 | x |
| 2002-12-31 | CA$3.04 | CA$0.05 | x |
| 2003-12-31 | CA$3.55 | CA$0.05 | x |
| 2004-12-31 | CA$0.79 | CA$0.05 | x |
| 2005-12-31 | CA$0.35 | CA$0.05 | x |
| 2006-12-31 | CA$1.38 | CA$0.05 | x |
| 2007-12-31 | CA$2.32 | CA$0.05 | x |
| 2008-12-31 | CA$1.38 | CA$0.05 | x |
| 2009-12-31 | CA$0.17 | CA$0.05 | x |
| 2010-12-31 | CA$-0.68 | CA$0.05 | x |
| 2011-12-31 | CA$-0.82 | CA$0.05 | x |
| 2012-12-31 | CA$0.09 | CA$0.05 | x |
| 2013-12-31 | CA$0.10 | CA$0.05 | x |
| 2014-12-31 | CA$0.28 | CA$0.05 | x |
| 2016-12-31 | CA$0.13 | CA$0.05 | x |
| 2017-12-31 | CA$0.14 | CA$0.05 | x |
| 2018-12-31 | CA$0.03 | CA$0.05 | x |
| 2019-12-31 | CA$-0.01 | CA$0.05 | x |
| 2020-12-31 | CA$-0.01 | CA$0.05 | x |
| 2021-12-31 | CA$0.02 | CA$0.05 | x |
| 2022-12-31 | CA$0.02 | CA$0.05 | x |
| 2023-12-31 | CA$0.02 | CA$0.05 | x |
| 2024-12-31 | CA$0.02 | CA$0.05 | x |
| 2025-12-31 | CA$0.00 | CA$0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Avricore Health Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -477.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -348.16%
- • Asset Turnover: 0.95x
- • Equity Multiplier: 1.45x
- Recent ROE (-477.14%) is below the historical average (-160.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -15.70% | 0.00% | 0.00x | 1.05x | CA$-20.55K |
| 2001 | -37.73% | -1944.40% | 0.02x | 1.03x | CA$-88.03K |
| 2002 | -29.23% | -1084.11% | 0.02x | 1.57x | CA$-71.78K |
| 2003 | -91.41% | -656.84% | 0.13x | 1.04x | CA$-811.50K |
| 2004 | -293.81% | -332.80% | 0.80x | 1.11x | CA$-823.40K |
| 2005 | -240.39% | -169.20% | 1.03x | 1.38x | CA$-394.04K |
| 2006 | -72.07% | -219.36% | 0.30x | 1.10x | CA$-640.08K |
| 2007 | -78.26% | -778.08% | 0.10x | 1.02x | CA$-2.19 Million |
| 2008 | -68.55% | -419.12% | 0.16x | 1.03x | CA$-1.36 Million |
| 2009 | -1668.50% | -273.53% | 1.08x | 5.65x | CA$-4.02 Million |
| 2010 | 0.00% | -613.75% | 1.60x | 0.00x | CA$-1.77 Million |
| 2011 | 0.00% | -367.76% | 4.22x | 0.00x | CA$-174.45K |
| 2012 | 64.90% | 0.00% | 0.00x | 1.83x | CA$239.76K |
| 2013 | -110.68% | 0.00% | 0.00x | 1.24x | CA$-800.26K |
| 2014 | -65.62% | -38520.01% | 0.00x | 1.06x | CA$-2.54 Million |
| 2015 | -86.84% | -1802.12% | 0.04x | 1.08x | CA$-3.14 Million |
| 2016 | -136.28% | -257.86% | 0.45x | 1.19x | CA$-2.81 Million |
| 2017 | -109.55% | -508.95% | 0.19x | 1.16x | CA$-2.99 Million |
| 2018 | -466.93% | -1826.85% | 0.19x | 1.35x | CA$-4.23 Million |
| 2019 | 0.00% | -6380.63% | 0.16x | 0.00x | CA$-2.06 Million |
| 2020 | 0.00% | -3554.24% | 0.08x | 0.00x | CA$-1.10 Million |
| 2021 | -77.75% | -1390.90% | 0.05x | 1.04x | CA$-1.93 Million |
| 2022 | -41.66% | -46.27% | 0.69x | 1.31x | CA$-1.01 Million |
| 2023 | -34.90% | -20.12% | 1.37x | 1.26x | CA$-902.11K |
| 2024 | -34.00% | -13.98% | 2.08x | 1.17x | CA$-865.75K |
| 2025 | -477.14% | -348.16% | 0.95x | 1.45x | CA$-1.90 Million |
Industry Comparison
This section compares Avricore Health Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,544,058
- Average return on equity (ROE) among peers: -199.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Avricore Health Inc (AVCR) | CA$389.56K | -15.70% | 0.45x | $3.66 Million |
| Spectral Med Inc (EDT) | $3.80 Million | -84.21% | 0.18x | $284.46 Million |
| Leveljump Healthcare Corp (JUMP) | $197.31K | -65.25% | 0.22x | $3.84 Million |
| StageZero Life Sciences Ltd (SZLS) | $1.73 Million | -625.72% | 2.46x | $3.58 Million |
| Telo Genomics Corp (TELO) | $449.24K | -24.20% | 0.04x | $4.00 Million |
About Avricore Health Inc
Avricore Health Inc. engages in the health data and point-of-care technologies business. It provides HealthTab, a turnkey point-of-care testing platform for pharmacies that can test up to 27 biomarkers on the spot for screening and managing chronic conditions, such as diabetes. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018… Read more